This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Urbà González, MD,PhD

Arch Dermatol. 2002;138:1604-1606.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major
Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH
N Engl J Med. 2002;346:891-895

Question: Is fluconazole effective and safe compared with placebo to treat cutaneous leishmaniasis caused by Leishmania major in immunocompetent adults?

Design: Alrajhi et al conducted a controlled clinical trial in Saudi Arabia using fluconazole for the treatment of cutaneous leishmaniasis caused by L major. In a 6-week placebo-controlled trial, 248 patients were screened, and 209 were allocated in the 2 groups using a random-number table. Sample size calculation was declared, and inclusion/exclusion criteria defined. Patients were observed for a mean of 72 days after the completion of the trial. The diagnosis was confirmed by parasitologic smear and/or culture, but the type of Leishmania was reported in only 27% of the randomized patients (all were . . . [Full Text of this Article]

Comment

Department of Dermatology, Clínica Plató, Barcelona, Spain

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?